Science Explorer Back to mapMap
Discussion
Institution · Comprehensive Cancer Center Erlangen

Most cited papers from Comprehensive Cancer Center Erlangen

Comprehensive Cancer Center Erlangen

What are the most cited papers from Comprehensive Cancer Center Erlangen?

The most cited paper from Comprehensive Cancer Center Erlangen is "Pembrolizumab for Early Triple-Negative Breast Cancer" (Peter Schmid et al., 2020), with 3,298 citations. Next come "Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial" (3,009) and "Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer" (2,689).

Showing 50 of 60 papers. Every paper with more than 222 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Pembrolizumab for Early Triple-Negative Breast Cancer Peter Schmid et al. · New England Journal of Medicine Open access 26 Feb 2020 3,298
2 Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial Axel Hauschild et al. · The Lancet 25 Jun 2012 3,009
3 Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer Gϋnter von Minckwitz et al. · New England Journal of Medicine Open access 5 Dec 2018 2,689
4 Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy Carsten Denkert et al. · The Lancet Oncology 8 Dec 2017 2,205
5 Association analysis identifies 65 new breast cancer risk loci Kyriaki Michailidou et al. · Nature Open access362 authors 20 Oct 2017 1,602
6 Resection of colorectal liver metastases Johannes Scheele, Richard Stang, A. Altendorf-Hofmann et al. · World Journal of Surgery 1995 1,545
7 Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes Nasim Mavaddat et al. · The American Journal of Human Genetics Open access269 authors 13 Dec 2018 1,213
8 Macrophage IL-10 Blocks CD8+ T Cell-Dependent Responses to Chemotherapy by Suppressing IL-12 Expression in Intratumoral Dendritic Cells Brian Ruffell, Debbie Chang-Strachan, Vivien W.-F. Chan et al. · Cancer Cell Open access 16 Oct 2014 1,016
9 Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition) Andrea Cossarizza et al. · European Journal of Immunology Open access436 authors Oct 2019 1,014
10 Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk Ganna Chornokur et al. · PLoS ONE Open access160 authors 19 Jun 2015 906
11 Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer Dennis J. Slamon et al. · New England Journal of Medicine Open access 11 Dec 2019 876
12 Randomized Study to Evaluate Sirolimus-Eluting Stents Implanted at Coronary Bifurcation Lesions Antonio Hugo Bezerra Colombo, Jeffrey W. Moses, Marie Claude Morice et al. · Circulation 24 Feb 2004 770
13 Technology in Parkinson's disease: Challenges and opportunities Alberto J. Espay et al. · Movement Disorders Open access 29 Apr 2016 681
14 RAD51B in Familial Breast Cancer Liisa M. Pelttari et al. · PLoS ONE Open access 5 May 2016 670
15 Parent-of-origin-specific allelic associations among 106 genomic loci for age at menarche Australian Ovarian Cancer Study et al. · Nature Open access202 authors 23 Jul 2014 667
16 MicroRNA Related Polymorphisms and Breast Cancer Risk Sofia Khan et al. · PLoS ONE Open access164 authors 12 Nov 2014 638
17 Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer BOCS et al. · Nature Genetics Open access248 authors 9 Mar 2015 638
18 CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus Dimitrios Mougiakakos, Gerhard Krönke, Simon Völkl et al. · New England Journal of Medicine Open access 4 Aug 2021 606
19 Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses Haoyu Zhang et al. · Nature Genetics Open access276 authors 18 May 2020 587
20 Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials Carsten Denkert et al. · The Lancet Oncology 9 Jul 2021 581
21 Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer Catherine M. Phelan et al. · Nature Genetics Open access420 authors 27 Mar 2017 566
22 Pros and cons of ultra-high-field MRI/MRS for human application Mark E. Ladd, Peter Bachert, Martin Meyerspeer et al. · Progress in Nuclear Magnetic Resonance Spectroscopy Open access 8 Jun 2018 552
23 Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial Sara A. Hurvitz, Miguel Martín, W. Fraser Symmans et al. · The Lancet Oncology Open access 24 Nov 2017 548
24 Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer Peter Schmid et al. · New England Journal of Medicine Open access 15 Sep 2024 544
25 Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer Australian Cancer Study et al. · Nature Genetics Open access443 authors 27 Mar 2013 544
26 Vascular occlusion by neutrophil extracellular traps in COVID-19 Moritz Leppkes et al. · EBioMedicine Open access 31 Jul 2020 479
27 Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer ABCTB Investigators et al. · Nature Genetics Open access476 authors 23 Oct 2017 477
28 Genetic insights into biological mechanisms governing human ovarian ageing Katherine S. Ruth et al. · Nature Open access274 authors 4 Aug 2021 468
29 The intestinal barrier: a pivotal role in health, inflammation, and cancer Markus F. Neurath, David Artis, Christoph Becker · ˜The œLancet. Gastroenterology & hepatology Open access 11 Mar 2025 463
30 Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial Michael Untch, Sibylle Loibl, Joachim Bischoff et al. · The Lancet Oncology 16 Jan 2012 459
31 Dose-Response Association of CD8 + Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer Ellen L. Goode et al. · JAMA Oncology Open access 19 Oct 2017 411
32 Hypoxia and Hypoxia-Inducible Factor-1α Modulate Lipopolysaccharide-Induced Dendritic Cell Activation and Function Jonathan Jantsch, Dipshikha Chakravortty, Nadine M. Turza et al. · The Journal of Immunology Open access Apr 2008 407
33 Prevalence and prognosis of Alzheimer’s disease at the mild cognitive impairment stage Stephanie J. B. Vos et al. · Brain Open access 17 Feb 2015 401
34 Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer Eric Hahnen et al. · JAMA Oncology Open access 17 Jul 2017 398
35 Ribociclib plus Endocrine Therapy in Early Breast Cancer Dennis J. Slamon et al. · New England Journal of Medicine 20 Mar 2024 395
36 Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study Nadia Harbeck et al. · Annals of Oncology Open access 15 Oct 2021 390
37 Global Consensus on Definition, Classification, Diagnosis, and Staging of Limbal Stem Cell Deficiency Sophie X. Deng, Vincent Michel Borderie, Clara C. Chan et al. · Cornea Open access 31 Dec 2018 380
38 [177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study Simron Singh, Daniel Halperin, Sten D. Myrehaug et al. · The Lancet Open access Jun 2024 370
39 GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer Australian Cancer Study et al. · Nature Genetics Open access170 authors 27 Mar 2013 363
40 Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer Hope S. Rugo et al. · JAMA Oncology Open access 23 Jan 2021 353
41 Pharmacokinetics and Pharmacodynamics of Remimazolam (CNS 7056) after Continuous Infusion in Healthy Male Volunteers Jürgen Schüttler, Andreas Eisenried, Marco Lerch et al. · Anesthesiology 16 Jan 2020 346
42 Identification of nine new susceptibility loci for endometrial cancer Tracy A. O’Mara et al. · Nature Communications Open access125 authors 3 Aug 2018 335
43 Triple-Negative Breast Cancer Risk Genes Identified by Multigene Hereditary Cancer Panel Testing Hermela Shimelis et al. · JNCI Journal of the National Cancer Institute Open access 5 Jun 2018 329
44 Brain membrane lipids in major depression and anxiety disorders Christian Philipp Muller, Martin Reichel, Christiane Mühle et al. · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids Open access 24 Dec 2014 317
45 FcRn: The Architect Behind the Immune and Nonimmune Functions of IgG and Albumin Michał Pyzik, Timo Räth, Wayne I. Lencer et al. · The Journal of Immunology Open access May 2015 301
46 Genetically Predicted Body Mass Index and Breast Cancer Risk: Mendelian Randomization Analyses of Data from 145,000 Women of European Descent Yan Ping Guo et al. · PLoS Medicine Open access111 authors 23 Aug 2016 293
47 Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival Dennis J. Slamon, Patrick Neven, Stephen Chia et al. · Annals of Oncology Open access 5 Jun 2021 291
48 Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group Carsten Denkert et al. · Modern Pathology Open access Jul 2016 289
49 High salt reduces the activation of IL-4– and IL-13–stimulated macrophages Katrina J. Binger et al. · Journal of Clinical Investigation Open access 20 Oct 2015 283
50 Transformer-based biomarker prediction from colorectal cancer histology: A large-scale multicentric study Sophia J. Wagner et al. · Cancer Cell Open access 30 Aug 2023 274

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.